Lv3
310 积分 2024-01-16 加入
Overall Survival with Inavolisib in PIK3CA -Mutated Advanced Breast Cancer
3个月前
已完结
Molecular classification of hormone receptor-positive HER2-negative breast cancer
3个月前
已完结
Molecular classification of hormone receptor-positive HER2-negative breast cancer
3个月前
已完结
Economic Evaluation of Sintilimab Plus Bevacizumab Versus Sorafenib as a First-line Treatment for Unresectable Hepatocellular Carcinoma
4个月前
已完结
Is Alpelisib Plus Fulvestrant Cost-Effective for Treating PIK3CA-Mutation, HR+/HER2− Advanced Breast Cancer in the USA?
4个月前
已完结
Cost Effectiveness of CDK4/6 Inhibitors in the First-Line Treatment of HR+/HER2− Metastatic Breast Cancer in Postmenopausal Women in the USA
5个月前
已完结
Cost Effectiveness of CDK4/6 Inhibitors in the First-Line Treatment of HR+/HER2− Metastatic Breast Cancer in Postmenopausal Women in the USA
5个月前
已完结
Outcomes of Various Classes of Oral Antidiabetic Drugs on Nonalcoholic Fatty Liver Disease
9个月前
已关闭
Inavolisib-Based Therapy in PIK3CA -Mutated Advanced Breast Cancer
9个月前
已完结
Inavolisib-Based Therapy in PIK3CA -Mutated Advanced Breast Cancer
9个月前
已完结
皖公网安备34019202002308
